Literature DB >> 7793137

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.

G E Hancock1, D J Speelman, P J Frenchick, M M Mineo-Kuhn, R B Baggs, D J Hahn.   

Abstract

The feasibility of employing a vaccine composed of the purified fraction 21 of Quillaja saponaria (QS-21) and the fusion (F) protein of respiratory syncytial virus (RSV) to induce protective immune responses in the lower respiratory tract of Balb/c mice was examined. Our goal was to compare local and systemic immune responses with those induced following immunization with the protein adsorbed to aluminium hydroxide (F/ALOH) adjuvant or by experimental infection. Sera from mice vaccinated with the QS-21 formulation (F/QS-21) contained elevated anti-F protein IgG antibody titres that were dependent on the dose of QS-21 employed. Similar to the immune responses generated by experimental infection, the sera from mice vaccinated with F/QS-21 possessed greater capacity to neutralize virus infectivity that was associated with the generation of heightened complement-fixing IgG2a antibody titres. In contrast, vaccination with F/ALOH elicited systemic immune responses that were characterized by a predominance of protein-specific antibodies of the IgG1 subclass and lower neutralizing antibody titres. The capacity of F/QS-21 to facilitate local pulmonary immune responses was also examined and found to be similar to those induced by experimental infection. After virus challenge, a 90-fold increase in the number of F protein-specific antibody-secreting cells was observed and associated with the clearance of virus from the infected lungs. Moreover, elevated levels of antigen-dependent killer cell activity were detected and appeared to be mediated by class I major histocompatibility complex restricted CD8+ T cells. Additional characterization of the pulmonary immune response was performed on the cellular infiltrates obtained after bronchoalveolar lavage and on formalin-fixed lung tissue. The local protective immune responses induced after challenge of the groups immunized with F/QS-21 or infectious virus were significantly different from those elicited in naive control mice injected with adjuvant alone, or in mice immunized with F/ALOH. The cellularity of the lavage fluids from the former groups was characterized by a significantly greater percentage of lymphocytes and less neutrophils. In similar fashion histological evaluation of the lungs from mice immunized with F/QS-21 or infectious virus revealed significantly elevated local immune responses after challenge. In conclusion, the results suggest that formulation with F/QS-21 alters the qualitative and quantitative nature of the immune response to the F glycoprotein when compared with the traditional aluminium-based adjuvants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793137     DOI: 10.1016/0264-410x(95)98263-a

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Authors:  I Mbawuike; Y Zang; R B Couch
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

2.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Stefanie N Vogel
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

4.  Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Authors:  M Oumouna; J W Mapletoft; B C Karvonen; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

7.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch.

Authors:  Sungsil Moon; Yuhuan Wang; Chris Edens; Jon R Gentsch; Mark R Prausnitz; Baoming Jiang
Journal:  Vaccine       Date:  2012-11-19       Impact factor: 3.641

Review 10.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.